Related references
Note: Only part of the references are listed.On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis
Christian Roever et al.
RESEARCH SYNTHESIS METHODS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects metaanalysis
Christian Roever et al.
RESEARCH SYNTHESIS METHODS (2021)
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
Ainhoa Madariaga et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann et al.
LANCET ONCOLOGY (2020)
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials
Ilary Ruscito et al.
CANCER TREATMENT REVIEWS (2020)
Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
Yifan Jiang et al.
FRONTIERS IN ONCOLOGY (2020)
Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
Amos Stemmer et al.
CANCERS (2020)
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Xuan Jiang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Stephanie Lheureux et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Real-World Impact of Survival by Period of Diagnosis in Epithelial Ovarian Cancer Between 1990 and 2014
San-Gang Wu et al.
FRONTIERS IN ONCOLOGY (2019)
Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review
Sudeep Gupta et al.
JOURNAL OF OVARIAN RESEARCH (2019)
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander et al.
BRITISH JOURNAL OF CANCER (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
M. Moschetta et al.
ANNALS OF ONCOLOGY (2016)
Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity
M. Koehler et al.
ANNALS OF ONCOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
Innovation in biologic new molecular entities: 1986-2014
Kathleen L. Miller et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors
J. Farres et al.
CELL DEATH AND DIFFERENTIATION (2015)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Adjusting for publication bias in the presence of heterogeneity
N Terrin et al.
STATISTICS IN MEDICINE (2003)
Share Paper
